首页|期刊导航|河北中医|基于T淋巴细胞亚群、肿瘤标志物及不良反应探究扶元复衡汤对中晚期非小细胞肺癌患者化疗的增效减毒作用

基于T淋巴细胞亚群、肿瘤标志物及不良反应探究扶元复衡汤对中晚期非小细胞肺癌患者化疗的增效减毒作用OA

Synergistic efficacy and toxicity-reducing effects of Fuyuan Fuheng Decoction in chemotherapy for patients with advanced and locally advanced non-small cell lung cancer:based on T-lymphocyte subsets,tumor markers,and adverse reactions

中文摘要英文摘要

目的 基于T淋巴细胞亚群、肿瘤标志物及不良反应探究扶元复衡汤对中晚期非小细胞肺癌(NSCLC)患者化疗的增效减毒作用.方法 将112 例中晚期NSCLC 患者根据治疗方案不同分为2 组,每组56 例.对照组采用含铂化疗方案治疗,研究组在对照组基础上联合扶元复衡汤,均治疗 3 个化疗周期.比较 2 组近期疗效、肿瘤标志物[鳞状细胞癌抗原(SCC)、神经元特异性烯醇化酶(NSE)、糖类抗原 125(CA125)、细胞角蛋白 19(CYFRA21-1)]、T 淋巴细胞亚群(CD3+、CD4+、CD4+/CD8+)、预后相关指标[β2 微球蛋白(β2-MG)、红细胞分布宽度(RDW)、D-二聚体(D-D)]、中医证候积分、卡氏功能状态评分(KPS)、肺癌患者生活质量测定量表(FACT-L)评分及不良反应情况.结果 研究组总有效率 82.14%(46/56),对照组总有效率 62.50%(35/56),研究组近期疗效优于对照组(P<0.05).2 组化疗 1、3 个周期后血清 SCC、NSE、CA125、CYFRA21-1 水平均较本组化疗前降低(P<0.05),研究组化疗 1、3 个周期后血清 SCC、NSE、CA125、CYFRA21-1 水平均低于对照组同期(P<0.05).2 组化疗 1、3 个周期后外周血 CD3+、CD4+、CD4+/CD8+水平均较本组化疗前降低(P<0.05),研究组化疗 1、3 个周期后外周血 CD3+、CD4+、CD4+/CD8+水平均高于对照组同期(P<0.05).2 组化疗 1、3 个周期后血清 β2-MG、RDW、D-D 水平均较本组化疗前降低(P<0.05),研究组化疗 1、3 个周期后血清β2-MG、RDW、D-D 水平均低于对照组同期(P<0.05).2 组化疗 1、3 个周期后中医证候积分均较本组化疗前降低(P<0.05),KPS、FACT-L 评分均升高(P<0.05),研究组化疗 1、3 个周期后中医证候积分均低于对照组同期(P<0.05),KPS、FACT-L 评分均高于对照组同期(P<0.05).研究组消化道反应、骨髓抑制、乏力不良反应发生率均低于对照组(P<0.05).结论 扶元复衡汤能减轻化疗对 NSCLC 患者 T 淋巴细胞亚群的影响,且能进一步下调血清肿瘤标志物水平,从而减少不良反应发生,起到增效减毒作用.

Objective To investigate the synergistic efficacy and toxicity-reducing effects of Fuyuan Fuheng Decoction in chemotherapy for patients with advanced and locally advanced non-small cell lung cancer(NSCLC),based on T-lymphocyte subsets,tumor markers,and adverse reactions.Methods A total of 112 patients with advanced and locally advanced NSCLC were divided into two groups according to treatment regimen,with 56 cases in each group.The control group received platinum-based chemotherapy,while the study group received Fuyuan Fuheng Decoction in addition to the treatment given to the control group.Both groups were treated for 3 chemotherapy cycles.Short-term efficacy,tumor markers(squamous cell carcinoma antigen[SCC],neuron-specific enolase[NSE],carbohydrate antigen 125[CA125],cytokeratin 19 fragment[CYFRA21-1]),T-lymphocyte subsets(CD3+,CD4+,CD4+/CD8+),prognosis-related indicators(β2-microglobulin[β2-MG],red blood cell distribution width[RDW],D-dimer[D-D]),traditional Chinese medicine(TCM)syndrome scores,Karnofsky performance status(KPS),Functional Assessment of Cancer Therapy-Lung(FACT-L)scores,and adverse reactions were compared between the two groups.Results The short-term efficacy in the study group was superior to that in the control group(82.14%[46/56]vs 62.50%[35/56],P<0.05).After 1 and 3 chemotherapy cycles,serum SCC,NSE,CA125,and CYFRA21-1 levels decreased in both groups compared with baseline(P<0.05),and the levels in the study group were lower than those in the control group at the same time points(P<0.05).After 1 and 3 chemotherapy cycles,peripheral blood CD3+,CD4+,and CD4+/CD8+levels decreased in both groups compared with baseline(P<0.05),while these indices were higher in the study group than in the control group at the same time points(P<0.05).After 1 and 3 chemotherapy cycles,serum β2-MG,RDW,and D-D levels decreased in both groups compared with baseline(P<0.05),and were lower in the study group than in the control group at the same time points(P<0.05).After 1 and 3 chemotherapy cycles,TCM syndrome scores decreased in both groups compared with baseline(P<0.05),whereas KPS and FACT-L scores increased(P<0.05).The study group had lower TCM syndrome scores and higher KPS and FACT-L scores than the control group at the same time points(P<0.05).The incidences of gastrointestinal reactions,myelosuppression,and fatigue were lower in the study group than in the control group(P<0.05).Conclusion Fuyuan Fuheng Decoction can alleviate the impact of chemotherapy on T-lymphocyte subsets in patients with NSCLC and further reduce serum tumor marker levels,thereby lowering the risk of adverse reactions and exerting synergistic efficacy and toxicity-reducing effects.

崔寅箫;穆美玲

陕西中医药大学附属医院肿瘤医院二病区,陕西 咸阳 712000陕西中医药大学第二附属医院肿瘤乳腺外科,陕西 咸阳 712046

医药卫生

非小细胞肺癌化疗中西医结合疗法

Non-small cell lung cancerChemotherapyIntegrated traditional Chinese and Western medicine therapy

《河北中医》 2026 (8)

1247-1252,6

陕西省自然科学基础研究计划项目(编号:2023-JC-YB-667)

10.3969/j.issn.1002-2619.2026.08.003

评论